Glesatinib hydrochloride is primarily used in the field of oncology as a targeted therapy for certain types of cancer. It functions as a dual inhibitor of MET and AXL receptor tyrosine kinases, which are often implicated in tumor growth, metastasis, and resistance to treatment. This compound is particularly investigated for its potential in treating non-small cell lung cancer (NSCLC), especially in cases where tumors exhibit MET or AXL dysregulation. By blocking these signaling pathways, it aims to inhibit cancer cell proliferation and improve patient outcomes. Clinical trials are ongoing to evaluate its efficacy and safety in various cancer types, with a focus on its ability to overcome resistance to other therapies.